Información de la revista
Vol. 24. Núm. S6.Diciembre 2004
Páginas 0-235
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 24. Núm. S6.Diciembre 2004
Páginas 0-235
Bibliografía
Acceso a texto completo
Bibliografía
Visitas
3566
Sociedad Española de Nefrología
Este artículo ha recibido
3566
Visitas
Información del artículo
Texto completo
Descargar PDF
Estadísticas
Texto completo
NEFROLOGÍA. Volumen 24. Suplemento Nº 6 · 2004 Bibliografía 1. Foley RN, Parfrey PS, Sarnak MJ. Cardiovascular disease in chronic renal disease: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis:32 (Suppl 3):S112-S119, 1998. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med:339:799-805, 1998. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis : 32 (Suppl 3): S5-S13, 1998. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis: 35 (Suppl 1): S117-S131, 2000. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27: 347-54, 1996. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril : the HOPE randomized trial. Ann Intern Med 134: 629-636; 2001. Ruilope KM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H y cols. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 12: 218-225; 2001. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL y cols. Kidney disease as a risk factor to recurrent cardiovascular disease and mortality. Am J Kidney Dis 44: 198-206: 2004. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL y cols. Kidney disease as a risk factor to recurrent cardiovascular disease and all-cause mortality: a pooled analysis of community-based study. J Am Soc Nephrol 15: 1307-15, 2004. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 351: 1344-1346, 2004. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA Izzo Jr y cols. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA: 289: 2560­2572, 2003. European Society of Hypertension - European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens: 21: 1011-1053, 2003. Annual Report: ESRD clinical perfomance measures project. Am J Kidney Dis: 39 (Suppl 2) S4-S61, 2002. 25. 16. Amenábar JJ, García-López F, Robles NR, Saracho R por el Comité de Registros de la SEN. Informe de diálisis y trasplante de la Sociedad Española de Nefrología y Registros Autonómicos correspondientes al año 1999. Nefrología 21: 246-252, 2001. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med: 347: 1256-1261, 2002. Burden R, Dasgupta I. How good are nephrogists at controlling blood pressure in renal patients. Nephrol Dial Transplant: 15: 440-441, 2000 Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA. Slowing the progression of chronic renal insufficiency. CAMJ: 166: 906-907, 2002. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJG, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol: 12: 1713-1720, 2001. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. Am J Hypertens:14:1219-25, 2001. Best PJ, Reddan DN, Berger PB, Szczech LA. McCullough, Califf RM. Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J 148; 230-242, 2004. Nickolas TL, Frisch GD, Opotowsky AR, Arons R, Radhakrishnan J. Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis 44: 185-197, 2004. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL y cols. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation:108:2154-2169, 2003. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, y cols. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Ann Intern Med: 139: 137-147, 2003. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis: 39 (Suppl 1): S1-S266, 2002. K/DOQI Clinical Practice Guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis: 41 (Suppl 3): S1-S89, 2003. Levey AS, Coresh J. Should the K/DOQI definition of chronic kidney disease be changed? Am J Kidney Dis: 42:626-630, 2003. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (suppl 1): S1-S290, 2004. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA Izzo Jr y cols. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and 2. 17. 18. 3. 4. 19. 5. 20. 6. 21. 7. 22. 23. 8. 24. 9. 10. 11. 26. 12. 13. 27. 28. 14. 29. 15. 30. 187 BIBLIOGRAFÍA Treatment of High Blood Pressure. JNC 7-complete version. Hypertension: 42: 1206-52, 2003. 31. 32. European best practice guidelines for hemodialysis (Part 1). Nephrol Dial Transplant: 17 (Suppl 7): S1 ­ S109, 2002. European best practice guidelines for renal transplantation (Part 2). Nephrol Dial Transplant: 17 (Suppl 4): S1 ­ S67, 2002. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization/International Society of Hypertension statement on management of hypertension J Hypertens 2003: 21: 1983-1992. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF y cols. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV):summary. BMJ 328: 634-40, 2004. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J y cols. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J: 24: 1601-1610, 2003. Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2002. Hipertensión: 19 (Supl 3): S1-S74. Actualizada a 1-03-2003 en http://www.seh-lelha.org/, 2002 Brotons C, Royo-Bordonada MA, Álvarez-Sala L, Armario P, Artigao R, Conté P y cols. Adaptación española de la guía europea de prevención cardiovascular. Nefrología 24: 31228,2004. López Bescós L, Arós Borau F, Lidón Corbi RM Cequier Fillat A, Bueno H, Alonso JJ, y cols. Actualización (2002) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en angina inestable /infarto sin elevación del segmento ST. Rev Esp Cardiol: 55: 631 ­ 642. 2002. Guía de práctica clínica sobre hipertensión arterial. Servicio Vasco de Salud. Vitoria, pp1-106, 2002. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: strategies to control, combat, and cure. Lancet: 359: 593-630, 2002. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ: 324: 71-86, 2002. Executive summary oh the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: 285: 2486-2497, 2001. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS y cols. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. Circulation: 104: 2996-3007, 2001. Cain AE, Khalil RA: Pathophysiology of essential hypertension: role of the pump, the vessel, and the kidney. Semin Nephrol 22: 3-16, 2002. Oparil S, Zaman MA, Calhoun DA: Pathogenesis of hypertension. Ann Intern Med 139: 761-776, 2003. Ritz E, Adamczak M, Zeier M: Kidney and hypertension-causes. Update 2003. Herz 28: 663-667, 2003. Cusi D, Barlassina C, Taglietti MV: Genetics of human hypertension. J Nephrol 16: 609-615, 2003. 48. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ: Oxidative stress, renal infiltration of immune cells, and saltsensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: F606-F616, 2004. Weinberger MH: Salt sensitivity of blood pressure in humans. Hypertension 27: 481-490, 1996. Hall JE: The kidney, hypertension, and obesity. Hypertension 41 (3 Pt 2): 625-633, 2003. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease: Executive summary. Am J Kidney Dis 43 (Suppl 1): S16-S41, 2004. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (Suppl 3): S112-S119, 1998. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, y cols: Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn study. Kidney Int 62: 1402-1407, 2002. Locatelli F, Bommer J, London GM, Martín-Malo A, Wanner C, Yaqoob M, y cols: Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 16: 459-468, 2001. Prichard S: Risk factors for coronary artery disease in patients with renal failure. Am J Med Sci 325: 209-213, 2003. Zoccali C, Mallamaci F, Tripepi G: Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl: 63 (Suppl 85):S105-S110; 2003. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J: The prevalence of non-traditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140: 9-17; 2004. Kasiske BL: Cardiovascular disease after renal transplantation. Semin Nephrol 20: 176-187; 2000. Tyralla K, Amann K: Morphology of the heart and arteries in renal failure. Kidney Int Suppl: 63 (Suppl 84):S80-S83, 2003. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E: Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 60 (suppl 1): S13-21, 2003. Safar ME, London GM, Plante GE: Arterial stiffness and kidney function. Hypertension 43: 163-168, 2004. London GM: Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 17 (Suppl 1): 29-36, 2002. Campistol JM: Uremic myopathy. Kidney Int 62: 1901-1913, 2002. London GM: Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 16: 85-94, 2003. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D: Predictors of new-onset kidney disease in a communitybased population. JAMA 291: 844-850, 2004. Chen J, Muntner P, Hamm LH, Jones DW, Batuman V, Fonseca V, y cols. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140: 167-174, 2004. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, y cols. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Diseases (AASK). Kidney Int 51: 244-252, 1997. 49. 50. 51. 33. 52. 34. 53. 35. 54. 36. 55. 56. 37. 38. 57. 39. 40. 58. 59. 60. 41. 61. 62. 63. 64. 65. 42. 43. 44. 66. 45. 46. 47. 67. 188 BIBLIOGRAFÍA 68. Harvey JM, Howie AJ, Lee SJ, Newbold KM, Adu D, Michael J, y cols. Renal biopsy findings in hypertensive patient with proteinuria. Lancet 340:1435-1436, 1992. Luke RG: Hypertensive nephrosclerosis: pathogenesis and prevalence. Nephrol Dial Transplant 14:2271-2278, 1999. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 49: 578-597, 1996. Wardle EN: Renal collagen synthesis and its control. Nephron 83: 106-110, 1999. Isaka Y, Akagi Y, Ando Y, Tsujie M, Imai E: Cytokines and glomerulosclerosis. Nephrol Dial Transplant 14: 30-32 1999. Luft FC: Hypertensive nephrosclerosis-a cause of end stage renal disease ? Nephrol Dial Transplant 15: 1515-1517, 2000. Brown DM, Provoost AP, Daly MJ, Lander ES, Jacob HJ: Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nature Genet 12: 44-51, 1996. Bergman S, Key BO, Kirk KA, Warnock DG, Rostand SG: Kidney disease in the first-degree relatives of AfricanAmericans with hypertensive end-stage renal disease. Am J Kidney Dis 27: 341-346, 1996. O`Dea DF, Murphy SW, Hefferton D, Parkfrey PS: Higher risk for renal failure in first-degree relatives of white patients with end-stage renal disease: A population based study. Am J Kidney Dis 32: 794-801, 1998. Marcantoni C, Ma L-J, Federspiel C, Fogo AB: Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 62: 172-180, 2002. Hollenberg NK: Renal function in the patient with hypertension. Med Clin North Am 88: 131-140, 2004. Kincaid-Smith P: Hypothesis: Obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled `hypertensive nephrosclerosis'. J Hypertens 22: 1051-1055, 2004. Andronico G, Ferraro-Monterello R, Mangano MT, Rome M, Rasputi F, Pinto A, y cols. Insulin resistance and glomerular haemodynamics and essential hipertensión. Kidney Int 62: 1005-1009, 2002. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, y cols. Insulin resistance and risk of chronic kidney disease in non-diabetic US adults. J Am Soc Nephrol 14: 469-477, 2003. Bloch MJ, Basile J: The diagnosis and management of renovascular disease: a primary care perspective. Part I. Making the diagnosis. J Clin Hypertens 5: 210-218, 2003. Zoccali C, Mallamaci F, Finocchiaro P: Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. J Am Soc Nephrol 13 (Suppl 3): S179-S183, 2002. Nally JV, Barton DP: Contemporary approach to diagnosis and evaluation of renovascular hypertension. Urol Clin North Am 28: 781-791, 2001. Lerman L, Textor SC: Pathophysiology of ischemic nephropathy. Urol Clin North Am 28: 793-803, 2001. Mailloux LU, Napolitano B, Bellucci AG, Vernace M, Wilkes BM, Mossey RT: Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: A 20-year clinical experience. Am J Kidney Dis 24: 622-629, 1994. 87. Murphy TP, Rundback JH, Cooper C, Kiernan MS: Chronic renal ischemia: implications for cardiovascular disease risk. J Vasc Interv Radiol 13: 1187-1198, 2002. Modi K, Rao VK: Atheroembolic renal disease. J Am Soc Nephrol 12: 1781-1787, 2001. Scoble JE: Atherosclerotic nephropathy. Kidney Int Suppl: 56 (Suppl 71): S106-S109; 1999. Coresh J, Astor B, Sarnak MJ: Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 13: 73-81, 2004 Keane WF, Eknoyan G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 33: 10041010, 1999. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 112, 2003. McClellan WM, Knight DF, Karp H, Brown WW: Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis 29: 368375, 1997. Locatelli F, Del Vecchio L, Pozzoni P: The importance of early detection of chronic kidney disease. Nephrol Dial Transplant 17: S2-S7, 2002. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 136: 604-615, 2002. Rossert J, Fouqueray B, Jacques Boffa J: Anemia management and delay of chronic renal failure progression. J Am Soc Nephrol 14: S173-S177, 2003. Górriz JL, Sancho A, Pallardó LM, Amoedo ML, Martín M, Sanz P, y cols. Significado pronóstico de la diálisis programada en pacientes que inician tratamiento sustitutivo renal. Un estudio multicéntrico español. Nefrología 22: 49-59, 2002. De Francisco ALM, Fernández-Fresnedo G: Llegada tardía a diálisis como consecuencia de insuficiencia renal no identificada. Nefrología 22: 95-97, 2002. Levinsky NG: Specialist evaluation in chronic kidney disease: too little, too late. Ann Intern Med 137: 542-543, 2002. 69. 70. 71. 72. 73. 88. 89. 90. 91. 74. 92. 75. 93. 76. 94. 77. 95. 78. 79. 96. 97. 80. 98. 81. 99. 82. 83. 100. Obrador GT, Arora P, Kausz AT, Ruthazer R, Pereira BJ, Levey AS: Level of renal function at the initiation of dialysis in the U.S. end-stage renal disease population. Kidney Int 56: 2227-2235, 1999. 101. United States Renal Data System: Excerpts from the 2000 U.S. Renal Data System Annual Data Report: Atlas of End Stage Renal Disease in the United States. Am J Kidney Dis 36: S1-S279, 2000. 102. Stengel B, Billon S, van Dijk PCW, Jager KJ, Dekker FW, Simpson K, y cols. on behalf of the ERA-EDTA Registry Committee: Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 18: 1824-1833, 2003. 103. Amenábar JJ, García F, Robles NR, Saracho R, Pinilla J, Gentil MA, y cols. Informe de diálisis y trasplante de la Sociedad Española de Nefrología y Registros Autonómicos, año 2000. Nefrología 22: 310-317, 2002. 84. 85. 86. 189 BIBLIOGRAFÍA 104. De Francisco ALM, Otero A: Epidemiología de la enfermedad renal crónica en España. Nefrología 23; 475-477, 2003. 105. Otero A, Abelleira A, Camba MJ, Pérez C, Armada E, Esteban J, y cols. Prevalencia de insuficiencia renal oculta en la provincia de Ourense. Nefrología 23 (suppl 6): 26, 2003. 106. Simal F, Martín JC, Bellido J, Arzúa D, Mena FJ, González I, y cols. Prevalencia de la enfermedad renal crónica leve y moderada en población general. Nefrología 24: 329-337, 2004. 107. Gorostidi M, Alonso JL, González de Cangas B, Jiménez F, Vaquero F, Moína MJ, y cols. Prevalencia de insuficiencia renal en población de edad avanzada y factores asociados. Resultados preliminares. XXXIV Congreso Nacional de la SEN. Resumen en Nefrología 24 , 2004 (en prensa). 108. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, y cols. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? what do we need to learn? where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906, 1998. 109. Mann JFE, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, y cols. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomised study. J Am Soc Nephrol 14: 641-647, 2003. 110. Smith HW: Measurement of the filtration rate, in The Kidney: Structure and Function in Health and Disease (chap 3), New York, Oxford University Press, 1951: 39-62, 143-202. 111. Levey AS: Measurement of renal function in chronic renal disease. Kidney Int 38: 167-184, 1990. 112. Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38: 1933-1953, 1992. 113. Perrone RD, Steinman TI, Beck GJ, Skibinski CI, Royal HD, Lawlor M y cols. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99Tc-DTPA, and inulin. Am J Kidney Dis 16: 224-235, 1990. 114. Dalmeida W, Suki WN: Measurement of GFR with nonradioisotopic radio contrast agents. Kidney Int 43: 725-728, 1988. 115. Krutzén E, Bäck SE, Nilsson-Ehle I, Nilsson-Ehle P: Plasma clearance of a new contrast agent, iohexol: a method for the determination of glomerular filtration rate. J Lab Clin Med 104, 955-61, 1984. 116. Brandstrom E, Grzegorczyk A, Jacobsson L: GFR measurements with iohexol and 51Cr-EDTA. A comparison of the two favoured GFR markers in Europe. Nephrol Dial Transplant 38: 1176, 1998. 117. Nilsson-Ehle P, Grubb A: New markers for the determination of GFR: iohexol clearance and cystatin C concentration. Kidney Int 46 (suppl 47), S17-S19, 1994. 118. Walser M: Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 32: 23-31, 1998. 119. Rodrigo E, Martín de Francisco AL, Escallada R, Ruiz JC, Fresnedo GF, Piñera C, Arias M. Measurement of renal function in pre-ESRD patients. Kidney Int 61 (suppl 80): S11-S17, 2002. 120. Molitch ME, Rodman E, Hirsch CA, Dubinsky E: Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med 93: 280, 1980. 121. Doolan PD, Alpen EL, Theil GB: A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med 32: 65-79, 1962. 122. Mitch WE, Walser M: A proposed mechanism of reduced creatinine excretion in severe chronic renal failure. Nephron 21: 248-254, 1978. 123. Mitch WE, Collier VU, Walser M: Creatinine metabolism in chronic renal failure. Clin Sci 58: 327-335, 1980. 124. Jones JD, Burnett PC: Implication of creatinine and gut flora in the uremic syndrome: induction of creatininase in colon contents of the rat by dietary creatinine. Clin Chem 18: 280284, 1972. 125. Kopple JD, Chumlea WC, Gassman JJ, Hotlinger DL, Maroni BJ, Merrill D, y cols. Relationship between GFR and nutritional status-Results from the MDRD study. J Am Soc Nephrol 6: 335, 1994 (abstr). 126. Pollock CA: Protein intake in renal disease. J Am Soc Nephrol 8: 777-783, 1997. 127. Ikitzler TA, Greene JH, Wingard RL, Parker RA, Hakim RM: Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol 6: 1386-1391, 1995. 128. Rowe JW, Andres R, Tobin JD, Nomis AN, Shock NW: The effect of age on creatinine clearance in men: a cross sectional and longitudinal study. J Gerontol 31:155-163, 1976. 129. Sinton TC, De Leacy EA, Cowley DM: Comparison of 51Cr EDTA clearance with formulae in the measurement of glomerular filtration rate. Pathology 18: 445-447, 1986. 130. Shemesh O, Golbetz H, Kriss JP, Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28: 830-838, 1985. 131. Bauer JH, Brooks CS, Burch RN: Renal function studies in man with advanced renal insufficiency. Am J Kidney Dis 11: 30-35, 1982. 132. Walser M, Drew HH, LaFrance ND: Creatinine measurements often yield false estimates of progression in chronic renal failure. Kidney Int 34: 412-418, 1988. 133. Levey AS, Bosch JP, Breyer-Lewis J, Greene T, Rogers N, Roth A: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130: 461-470, 1999. 134. Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, y cols. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 38: 744-753, 2001. 135. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976. 136. Rolin HA, May PM, Wei R: Inaccuracy of estimated creatinine clearance for prediction of iothalamate glomerular filtration rate. Am J Kidney Dis 4: 48-54, 1984. 137. Toto RD, Kirk KA, Coresh J, Jones C, Appel L, Wright J, y cols. Evaluation of serum creatinine for estimating glomerular filtration rate in African Americans with hypertensive nephrosclerosis: Results from the African-American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 8: 279287, 1997. 138. Walser M, Drew HH, Guldan JL: Prediction of glomerular filtration rate from serum creatinine concentration in advanced chronic renal failure. Kidney Int 44: 1145-1148, 1993. 139. Coresh J, Toto RD, Kirk KA, Whelton PK, Massry S, Jones C, y cols. Creatinine clearance as a measure of GFR in screenes 190 BIBLIOGRAFÍA for the African-american study of kidney disease and hypertension pilot study. Am J Kidney Dis 32: 32-42, 1998. 140. Levey AS, Greene T, Jusek J, Beck GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: A1828, 2000. 141. Vervoort G, Willems HL, Wetzels JFM: Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 17: 1909-1913, 2002. 142. Bostom AG, Kronenberg F, Ritz E: Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13: 2140-2144, 2002. 143. Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, y cols. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis 43: 112-119, 2004. 144. Lin J, Knight EL, Hogan ML, Singh AK: A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 14: 25732580, 2003. 145. Nankivell BJ, Gruenewald SM, Allen RDM, Chapman JR: Predicting glomerular filtration rate after kidney transplantation. Transplantation 59: 1683-1689, 1995. 146. Mourad A, Carney S, Gillies A, Hibberd A, Trevillian P, Nanra R: Measurement of glomerular filtration rate in renal transplant recipients: a comparison of methods. Nephrology 7: 77-82, 2002. 147. Stoves J, Lindley EJ, Barnfield MC, Burniston MT, Newstead CG: MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. Nephrol Dial Transplant 17: 2036-2037, 2002. 148. Mariat C, Alamartine E, Barthelemy JC, de Filippis JP, Thibaudin D, Berthoux P, y cols. Assessing renal graft function in clinical trials: can test predicting glomerular filtration rate substitute for a reference method? Kidney Int 65: 289297, 2004. 149. Goldberg TH, Finkelstein MS: Difficulties in estimating glomerular filtration rate in the elderly. Arch Intern Med 147: 1430-1433, 1987. 150. Brion LP, Boeck MA, Gauthier B: Estimation of glomerular filtration rate in anorectic adolescents. Pediatr Nephrol 3: 16-21, 1989. 151. Skluzacek PA, Szewc RG, Nolan CR, Riley D, Lee S, Pergola PE: Prediction of GFR in liver transplant candidates. Am J Kidney Dis 42: 1169-1176, 2003. 152. Knight EL, Verhave JC, Spiegelman D, Hillege HL, De Zeeuw D, Curhan GC, y cols. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65: 1416-1420, 2004. 153. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR: Screening for proteinuria in US adults. A cost effectiveness analysis. JAMA 290: 3101-3114, 2003. 154. Fernández-Fresnedo G, Escallada R, Rodrigo E, De Francisco ALM, Cotorruelo JG, Sanz De Castro S, y cols. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 73:1345-8, 2002. 155. American Diabetes Association: Nephropathy in diabetes. Position statement. Diabetes Care 27: S79-S82, 2004. 156. Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuria. N Eng J Med 309: 1543-1546, 1983. 157. Schwab SJ, Christensen RL, Dougherty K, Klahr S: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 147: 943944, 1987. 158. Steinhäuslin F, Wauters JP: Quantitation of proteinuria in kidney transplant patients: accuracy of the urinary protein/creatinine ratio. Clin Nephrol 43: 110-115, 1995. 159. Torng S, Rigatto C, Rush DN, Nickerson P, Jeffery JR: The urine protein to creatinine ratio (P/C) as a predictor of 24hour urine protein excretion in renal transplant patients. Transplantation 72: 1453-1456, 2001. 160. Rodrigo E, Piñera C, Ruiz JC, Fernández-Fresnedo G, Escallada R, Herráez I, y cols. Quantitation of 24-hour urine protein excretion in kidney transplant patients by the use of protein to creatinine ratio. Transplant Proc 35: 702, 2003. 161. Zelmanovitz T, Gross JL : Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy. Diabetes Care 21: 1076-1079, 1998. 162. Rodby RA, Rohde RD, Sharon Z, Pohl MA, Bain RP, Lewis EJ: The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. Am J Kidney Dis 26: 904-909, 1995. 163. Chitalia VC, Kothari J, Wells EJ, Livesey JH, Robson RA, Searle M: Cost-benefit analysis and prediction of 24-hour proteinuria from spot urine protein-creatinine ratio. Clin Nephrol 55: 436-447, 2001. 164. Risberg A, Larsson A, Olsson K, Lyrenas S, Sjoquist M: Relationship between urinary albumin and albumin/creatinine during normal pregnancy and pre-eclampsia. Scand J Clin Lab Invest 64: 17-23, 2004. 165. Nathan DM, Rosenbaum C, Protasowicki VD: Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 10: 414-418, 1987. 166. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo M: The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 20: 516-519, 1997. 167. Ahn CW, Song YD, Kim JH, Lim SK, Choi KH, Kim KR, y cols. The validity of random urine specimen albumin measurement as a screening test for diabetic nephropathy. Yonsei Med J 40: 40-45, 1999. 168. Ng WY, Lui KF, Thai AC: Evaluation of a rapid screening test for microalbuminuria with spot measurement of urine albumin-creatinine ratio. Ann Acad Med Singapore 29: 62-65, 2000. 169. James MA, Fotherby MD, Potter JF: Screening tests for microalbuminuria in non-diabetic elderly and their relation to blood pressure. Clin Sci 88: 185-190, 1995. 170. Mosca A, Paleari R, Ceriotti F, Lapolla A, Fedele D: Biological variability of albumin excretion rate and albuminto-creatinine ratio in hypertensive type 2 diabetic patients. Clin Chem Lab Med 41: 1229-1233, 2003. 171. Jacobs DR, Murtaugh MA, Steffes M, Yu X, Roseman J, Gotees FO: Gender- and race-specific determination of albumin excretion using albumin-to-creatinine ratio in single, untimed urine specimen. The Coronary Artery Risk Development in Young adults Study. Am J Epidemiol 155: 1114-1119, 2002. 191 BIBLIOGRAFÍA 172. Matixx HJ, Hsu C-Y, Shaykevich S, Curhan G: Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 13: 1034-1039, 2002. 173. Tamura S, Shimizu T, Kawakatsu H, Tateishi S: Correlation between 24-hour urinary protein excretion and protein/creatinine ratio in the first voided morning urine sample. Nippon Jinzo Gakkai Shi 46: 26-34, 2004. 174. Wachtell K, Visen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, y cols. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139: 901-906, 2003. 175. Meinhardt U, Ammann RA, Fluck C, Diem P, Mullis PE: Microalbuminuria in diabetes mellitus: efficacy of a new screening method in comparison with timed overnight urine collection. J Diabetes Complications 17: 254-257, 2003. 176. Gerber LM, Johnston K, Alderman MH: Assessment of a new dipstick test in screening for microalbuminuria in patients with hypertension. Am J Hypertens 11: 1321-1327, 1998. 177. Agarwal R, Panesar A, Lewis RR: Dipstick proteinuria: can it guide hypertension management? Am J Kidney Dis 39: 1190-1195, 2002. 178. Baskar V, Kamalakannan D, Holland MR, Catchpole CR, Singh BM. Uncertain clinical utility of contemporary strategies for microalbuminuria testing. Diabetes Obes Metab 5: 262-266, 2003. 179. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Kusek JW, y cols. Microalbuminuria in the US population: third National Health Nutrition Examination Survey. Am J Kidney Dis 39: 445-459, 2002. 180. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, y cols. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 42: 22-35, 2003. 181. Jensen JS, Clausen P, Borch-Johnsen K, Jensen G: Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 12 (suppl 2): 6-9, 1997. 182. Gai M, Motta D, Cantaluppi V, Fop F, Jeantet A, Segoloni GP, y cols. Proteinuria dipstick test: is it time to change? Kidney Int 63: 2326-2327, 2003. 183. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, y cols. Prevalence of kidney damage in australian adults: the AusDiab Kidney Study. J Am Soc Nephrol 14: S131-S138, 2003. 184. Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63: 1468-1474, 2003. 185. Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of proteinuria: the Framigham study. Am Heart J 108: 1347-1352, 1984. 186. Romundstad S, Holmen J, Kvenild K, Aakervik O, Hallan H: Clinical relevance of microalbuminuria screening in selfreported diabetic/non-hypertensive persons identified in a large health screening-the Nord-Trondelag Health Study (HUNT), Norway. Clin Nephrol 59: 241-251, 2003. 187. Topham PS, Jethwa A, Watkins M, Rees Y, Feehally J: The value of urine screening in a young adult population. Fam Pract 21: 18-21, 2004. 188. Iseki K, Iseki C, Ikemiya Y, Fukiyama K: Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 49: 800-805, 1996. 189. Allwall N, Lohi A. A population study on renal and urinary tract diseases. Acta Med Scand 194: 525-528, 1973. 190. Ruiz JC, López G. Técnicas de imagen en nefrología. En: Nefrología clínica. Hernando L, ed. Editorial Panamericana, 2º edición. Madrid 2003, 135-144. 191. Marín R, Gorostidi M, Pobes A: Hipertensión arterial y enfermedad vascular renal: nefroangioesclerosis. Nefrología 22 (suppl 1): 36-45, 2002. 192. Marín R, Gorostidi M: Nefroesclerosis. En: Hernando L, Aljama P, Arias M, Caramelo C, Ejido J, Lamas S, eds. Nefrología clínica. Madrid: Editorial Médica Panamericana: 221-232, 2003. 193. Ruilope LM: The kidney and cardiovascular risk. Nephrol Dial Transplant 12: 243-245, 1997. 194. Ruilope LM: The kidney as part of the cardiovascular system. J Cardiovasc Pharmacol 33 (suppl 1): S7-S10, 1999. 195. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF: Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38: 1782-1787, 2001. 196. Ruilope LM: The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 13: S165-S168, 2002. 197. Kasiske BL: The kidney in cardiovascular disease. Ann Intern Med 134: 707-709, 2001. 198. Campo C, Segura J, Ruilope LM: Riesgo cardiovascular asociado a la insuficiencia renal. Hipertensión 18: 285-290, 2001. 199. Pérez I, Luño J: La insuficiencia renal es un importante factor de riesgo cardiovascular. Nefrología 22: 306-309, 2002. 200. Ritz E: Minor renal dysfunction: an emerging independent cardiovascular risk factor. Heart 89: 963-964, 2003. 201. Ritz E, McClellan WM: Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol 15: 513-16, 2004. 202. Best PJ, Holmes DR: Chronic kidney disease as a cardiovascular risk factor. Am Heart J 145: 383-386, 2003. 203. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659-663, 2004. 204. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, y cols. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572, 2003. 205. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, y cols. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JNC 7 ­ Complete version. Hypertension 42: 1206-1252, 2003. 206. Guidelines Committee: 2003 European Society of Hypertension ­ European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053, 2003. 207. Culleton BF, Larson MG, Evans JC, Wilson PWF, Barrett BJ, Parfrey PS, y cols. Prevalence and correlates of serum creatinine levels. The Framingham Heart Study. Arch Intern Med 159: 1785-1790, 1999. 192 BIBLIOGRAFÍA 208. Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Parfrey PS, y cols. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56: 2214-2219, 1999. 209. Garg AX, Clark WF, Haynes RB, House AA: Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 61: 1486-1494, 2002. 210. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13: 745-753, 2002. 211. Henry RMA, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, y cols. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn study. Kidney Int 62: 1402-1407, 2002. 212. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 64: 610-615, 2003. 213. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, y cols. for the Cardiovascular Health Study Collaborative Research Group: Risk factors for 5-year mortality in older adults. The Cardiovascular Health Study. JAMA 279: 585-592, 1998. 214. Manjunath G, Tighiouart H, Coresh J, MacLeod B, Salem DN, Griffith JL, y cols. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63: 1121-1129, 2003. 215. Fried LP, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, y cols. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41: 1364-1372, 2003. 216. Shlipak MG, Fried LP, Stehman-Breen C, Siscovick D, Newman AB: Chronic renal insufficiency and cardiovascular events in the elderly: findings from the Cardiovascular Health Study. Am J Geriatr Cardiol 13: 81-90, 2004. 217. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, y cols. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension 13 (5 suppl): I80-93, 1989. 218. Flack J, Neaton J, Daniels B, Esunge P: Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis 21 (4 Suppl 1): 31-40, 1993. 219. Schillaci G, Reboldi G, Verdecchia P: High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 161: 886-891, 2001. 220. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, y cols. for the HOT study group: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755-1762, 1998. 221. Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, y cols. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study. J Hypertens 19: 1149-1160, 2001. 222. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isola- ted systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265: 3255-3264, 1991. 223. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, y cols. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350: 757-764, 1997. 224. Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group: Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 160: 211-220, 2000. 225. Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L, Bailey JE, y cols. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the Systolic Hypertension in the Elderly Program. Arch Intern Med 158: 1340-1345, 1998. 226. Wang JG, Staessen JA, Fagard RH, Birkenhäger WH, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Trial Collaborative Group: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 37: 1069-1074, 2001. 227. de Leeuw PW, Thijs L, Birkenhäger WH, Voyaki SM, Efstratopoulos AD, Fagard RH, y cols. for the Systolic Hypertension in Europe (Sist.-Eur) Trial Investigators: Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 13: 2213-2222, 2002. 228. Segura J, Campo C, Gil P, Roldán C, Vigil L, Rodicio JL, y cols. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 15: 1616-1622, 2004. 229. Matts JP, Karnegis JN, Campos CT, Fitch LL, Johnson JW, Buchwald H: Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. J Fam Pract 36: 497-503, 1993. 230. Anderson RJ, O´Brien M, MaWhinney S, VillaNueva CB, Moritz TE, Sethi GK, y cols. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int 55: 1057-1062, 1999. 231. Anderson RJ, O´Brien M, MaWhinney S, VillaNueva CB, Moritz TE, Sethi GK, y cols. Mild renal failure is associated with adverse outcome after cardiac valve surgery. Am J Kidney Dis 35: 1127-1134, 2000. 232. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35: 681-689, 2000. 233. Hillege HL, Girbes AR, de Kam PJ, Boomsma D, de Zeeuw D, Charlesworth A, y cols. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-210, 2000. 234. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, y cols. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 36: 679684, 2000. 235. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF: Are patients with renal failure good 193 BIBLIOGRAFÍA candidates for percutaneous coronary revascularization in the new device era? Circulation 102: 2966-2972, 2000. 236. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, Garg M, y cols. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 37: 1191-1200, 2001. 237. Szczech LA, Reddan DN, Owen WF, Califf R, Racz M, Jones RH, y cols. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 60: 292-299, 2001. 238. Hemmelgarn BR, Ghali WA, Ouan H, Brant R, Norris CM, Taub KJ, y cols. Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 37: 64-72, 2001. 239. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145-153, 2000. 240. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD, for the Heart and Estrogen/progestin Replacement Study (HERS) Investigators: Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 38: 705-711, 2001. 241. Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, y cols. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 40: 1801-1808, 2002. 242. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13: 1928-1936, 2002. 243. Mahon NG, Blackstone EH, Francis GS, Starling RC, Young JB, Lauer MS: The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 40: 1106-1113, 2002. 244. Soman SS, Sandberg KR, Borzak S, Hudson MP, Yee J, McCullough PA: The independent association of renal dysfunction and arrhythmias in critically ill patients. Chest 122: 669-677, 2002. 245. Walsh CR, O´Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM: Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. Am Heart J 144: 1003-1011, 2002. 246. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137: 555-562, 2002. 247. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, y cols. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137: 563-570, 2002. 248. McCullough PA, Nowak RM, Foreback C, Tokarski G, Tomlanovich MC, Khoury N, y cols. Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med 162: 2464-2468, 2002. 249. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, y cols. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106: 974-980, 2002. 250. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E; TACTICS-TIMI 18 Investigators: Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol 90: 1246-1249, 2002. 251. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, y cols. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39: 1113-1119, 2002. 252. Shaw RE, Anderson HV, Brindis RG, Krone RJ, Klein LW, McKay CR, y cols. Development of a risk adjustment mortality model using the American College of CardiologyNational Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. J Am Coll Cardiol 39: 1104-1112, 2002. 253. Szczech LA, Best PJ, Crowley E, Brooks MM, Berger PB, Bittner V, y cols. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation 105: 2253-2258, 2002. 254. Gruberg L, Weissman NJ, Waksman R, Laird JR Jr, Pinnow EE, Wu H, y cols. Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. Am J Cardiol 89: 54-57, 2002. 255. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41: 718-724, 2003. 256. Wison S, Foo K, Cunningham J, Cooper J, Deaner A, Knight C, y cols. Renal function and risk stratification in acute coronary syndromes. Am J Cardiol 91: 1051-1054, 2003. 257. Reinecke H, Trey T, Matzkies F, Fobker M, Breithardt G, Schaefer RM: Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int 63: 696-701, 2001. 258. Gruberg L, Weissman NJ, Pichard AD, Waksman R, Kent KM, Satler LF, y cols. Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. Am Heart J 145: 529-534, 2003. 259. Chae CU, Albert CH, Glynn RJ, Guralnik JM, Curhan GC: Mild renal insufficiency and risk of congestive heart failure in men and women 70 years of age. Am J Cardiol 92: 682686, 2003. 260. Santopinto JJ, Fox KAA, Goldberg RJ, Budaj A, Piñero G, Avezum A, y cols. on behalf of the GRACE Investigators: Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 89: 1003-1008, 2003. 261. Mogensen CE, Christensen CK : Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 8993, 1984. 262. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310: 356-360, 1984. 263. Casado S, Vázquez A, Sierra M, Caramelo C: Microalbuminuria: mecanismos y significado. Nefrología 17: 271-274, 1997. 264. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E: Proteinuria and mortality in diabetes: the WHO 194 BIBLIOGRAFÍA Multinational Study of Vascular Disease in Diabetes. Diabet Med 12: 149-155, 1995. 265. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303-1309, 1995. 266. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulindependent diabetic subjects. Stroke 27: 2033-2039, 1996. 267. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157: 1413-1418, 1997. 268. Valmadrid CT, Klein R, Moss SE, Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Inter Med 160: 1093-1100, 2000. 269. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 2: 530-533, 1998. 270. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 300: 297-300, 1990. 271. Wagner DK, Harris T, Madans JH : Proteinuria as a biomarker: risk of subsequent morbidity and mortality. Environ Res 66: 160-172, 1994. 272. Kuusisto J, Mykkanen L, Pyorala K, Laakso M:Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 91: 831-837, 1995. 273. Ljungman S, Wikstrand J, Hartford M, Berglund G: Urinary albumin excretion ­ a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 9: 770-778, 1996. 274. Agewall S, Wikstrand J, Ljungman S, Fagerberg B: Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes. Risk Factor Intervention Study Group. Am J Cardiol 80: 164-169, 1997. 275. Grimm RJ, Svendsen K, Kasiske B, y cols. Proteinuria as a risk factor for mortality over 10 years of follow-up. MRFIT Research Group: Multiple Risk Factor Intervention Trial. Kidney Int 63; S10-S14, 1997. 276. Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16: 1325-1333, 1998. 277. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, y cols. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 19: 617-624, 1999. 278. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19: 1992-1997, 1999. 279. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D: Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 109: 1-8, 2000. 280. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K: Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35: 898903, 2000. 281. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, y cols. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356: 366-372, 2000. 282. Roest M, Banga JD, Janssen WMT, Grobbee DE, Sixma JJ, de Jong PE, y cols. : Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 103: 3057-3061, 2001. 283. Diercks GF, Hillege HL, van Boven AJ, Kors JA, Crijns HJ, Grobbee DE, y cols. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol 40: 1401-1407, 2002. 284. Gerstein HC, Mann JFF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, y cols. for the HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001. 285. Hillege, HL, Fidler, V, Diercks, GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, y cols. for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002. 286. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjær H: Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis 42: 466-473, 2003. 287. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, y cols. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139: 901-906, 2003. 288. Segura J, Campo C, Ruilope LM: Proteinuria: an underappreciated risk factor in cardiovascular disease. Curr Cardiol Rep 4: 458-462, 2002. 289. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, y cols. for the LIFE study group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003, 2002. 290. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, y cols. for the LIFE study group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004-1010, 2002. 291. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL y cols. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42:1050-65, 2003. 292. Rigatto C. Clinical epidemiology of cardiac disease in renal transplant recipients. Semin Dial 16: 106-110, 2003. 195 BIBLIOGRAFÍA 293. Kasiske BL, Guijarro C, Massy Z,Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7: 158-65, 1996. 294. United States Renal Data System. USRDS 2002; Annual Data Report. Bethesda MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Available at: http://www.usrds.org/reference.htm, 2002 295. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ.Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol13:1918-27, 2002. 296. Cheung AK, Sarnak MJ, Yang G, Dwyer JT, Heyka RJ, Rocco MV y cols. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58: 353-62, 2000. 297. Locatelli F, Pozzoni P, Tentori F, del Vecchio L.Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant.18 (Suppl 7):S2-S9, 2003. 298. Zoccali C, Mallamaci F, Tripepi G. Novel Cardiovascular Risk Factors in End-Stage Renal Disease. J Am Soc Nephrol 15 (supl 1): S77-S80, 2004. 299. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11:1735-43, 2000. 300. Jindal RM, Hjelmesæth J. Impact and management of posttransplant diabetes mellitus. Transplantation 70 (11 Suppl): SS58­SS63, 2000. 301. Torregrosa JV. Cardiovascular risk and diabetogenicity associated with CNI use: a comparison between cyclosporine and tacrolimus. Transplant Int 2004 (en prensa) 302. Culleton BF, Wilson PW. Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. J Am Soc Nephrol 9: S5­15, 1998. 303. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, y cols. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 27: 347-54, 1996. 304. McMahon LP, Roger SD, Levin A, for the Slimheart Investigators group. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 15: 1640-47, 2004. 305. Wheeler DC, Townend JN, Landray MJ. Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Kidney Int (Supl. 84): S201-3, 2003. 306. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 11: 12771285, 1996. 307. Silberberg JS, Barre P, Prichard SS, Sniederman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290, 1989. 308. London GM, Pannier B, Guerin P, Blacher J, Marchais SJ, Darne B. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12: 2759-67, 2001. 309. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE.Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 54:1720-5, 1998. 310. Huting J, Kramer W, Schütterle G, Wizemann V. Analysis of left ventricular changes associated with chronic hemodialysis. Nephron 49: 284-90, 1998. 311. Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD. Impact of renal transplantation on uremic cardiomyopathy. Transplantation:60: 908-14, 1995. 312. Rigatto C, Foley RN, Kent GM, Guttmann R, Parfrey PS. Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 70:570-5, 2000. 313. Brahimi M, Dahan M, Dabire H, Levy BI. Impact of pulse pressure on degree of cardiac hypertrophy in patients with chronic uremia. J Hypertens 18: 1645-50, 2000. 314. Ventura JE, Tavella N, Romero C, Petraglia A, Baez A, Munoz L. Aortic valve calcification is an independent factor of left ventricular hypertrophy in patients on maintenance hemodialysis. Nephrol Dial Transplant 17: 1795-801, 2002. 315. London GM, Guerin AP, Marchais SJ, Pannier B, Safar M, Day M, y cols. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 50: 600-608, 1996. 316. Nitta K, Akiba T, Uchida K, Otsub S, Otsubo Y, Takei T y cols. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification. Hypertens Res 27: 47-52, 2004. 317. Fagugli RM, Pasini P, Quintaliani G, Pasticci F, Ciao G, Cicconi B, y cols. Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transplant. 18:2332-8, 2003. 318. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Candela V, Labate C, Tassone F.Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. J Hypertens 19:28793, 2001. 319. Hernandez D, Lacalzada J, Barragan A, Laynez I, Salido E, Barrios Y, y cols. Hipertrofia ventricular izquierda después del trasplante renal: prevención y tratamiento. Nefrología 24(supl IV): S43-S48, 2004. 320. Ritz E, Rambausek M, Mall G, Rufmann K, Mandelbaum A. Cardiac changes in uraemia and their possible relationship to cardiovascular instability on dialysis. Nephrol Dial Transplant 5(supl 1): 93-97, 1990. 321. Roig E, Betriu A, Castaner A, Magrina J, Sanz G, NavarroLopez F. Disabling angina pectoris with normal coronary arteries in patients undergoing long-term hemodialysis. Am J Med. 71:431-4, 1981. 322. Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant 5: 39-44, 1990. 323. Zoccali C, Benedetto FA, Mallamaci T, y cols. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12: 2768-2774, 2001. 324. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis. 40:1202-10, 2002. 325. Fathi R, Isbel N, Haluska B, Case C, Johnson DW, Marwick TH.: Correlates of subclinical left ventricular dysfunction in ESRD. Am J Kidney Dis 41: 1016-1025, 2003. 326. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996. 196
Idiomas
Nefrología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.